BTG Commences Phase IIa Study of Multiple Sclerosis BTG plc, 21 Jan 2010 Accessed on 20 Dec 2011 from http://www.btgplc.com/page/4894/btg-commences-phase-iia-study-of-pleneva8482-for-multiple-sclerosis.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) ClinicalTrials.gov Accessed on 20 Dec 2011 from http://clinicaltrials.gov/ct2/show/NCT01037907.
BTG plc Close Period Update BTG plc, 5 Oct 2011 Accessed on 20 Dec 2011 from http://www.btgplc.com/page/15627/btg-plc-close-period-update.